Tirzepatide has a well-characterized safety profile from the SURPASS and SURMOUNT clinical trial programs. Gastrointestinal side effects are the most common, similar to semaglutide.
Medical Disclaimer: This page is for informational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before using any research chemical or peptide. Tirzepatide is not FDA-approved for human use (unless noted).
Reported in approximately 25–33% of patients in clinical trials. Typically most pronounced during dose escalation.
Reported in approximately 17–23% of patients. Usually mild to moderate.
Reported in approximately 8–13% of patients. Decreases with continued use.
Reported in approximately 11–17% of patients.
Significant appetite reduction is both a therapeutic effect and a reported side effect.
Mild redness, swelling, or itching at the injection site reported in approximately 3–7% of patients.
Rare but serious. Contraindicated in patients with history of pancreatitis.
Increased risk of gallstones, particularly with rapid weight loss.
Black box warning: tirzepatide caused thyroid C-cell tumors in rodents. Contraindicated in patients with personal or family history of MTC or MEN2.
Risk increased when combined with insulin or sulfonylureas.
Rare cases reported, likely secondary to dehydration from GI side effects.
Tirzepatide should not be used in the following situations:
Nausea, diarrhea, vomiting, and constipation are the most common side effects, particularly during dose escalation. These typically improve over time.
Clinical trials suggest tirzepatide and semaglutide have similar GI side effect profiles, though tirzepatide may have slightly lower rates of nausea at equivalent efficacy doses.
Nausea is typically most intense during the first 4–8 weeks and during each dose escalation. Most patients report significant improvement after 2–3 months.
Rapid weight loss from tirzepatide can include lean mass loss. Adequate protein intake and resistance exercise are recommended to preserve muscle mass during treatment.
The SURPASS-CVOT trial showed tirzepatide reduced major adverse cardiovascular events by 15% compared to placebo in high-risk patients with type 2 diabetes.
Purgo Labs provides HPLC-verified, third-party tested Tirzepatide for legitimate research purposes. Every batch includes a certificate of analysis.
Shop Tirzepatide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.